- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04237402
Demonstration of the Presence of a Carbonyl Stress in the Hair Follicles of Postpartum Women
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
At the cutaneous level, oxidative stress induces the formation of carbonyl compounds which, by binding to proteins, produce non-functional adducts inducing cutaneous aging. This mechanism is called "carbonyl stress".
During pregnancy, estrogen increases massively, stimulates the whole body and prolongs the life of the hair (slower passage in telogen phase).
After delivery, estrogen levels drop, resulting in a massive and simultaneous hair loss that should have "naturally" fallen earlier. In addition, birth is a stressful stage for most moms. This stress and excessive fatigue and possibly a return to work may also be responsible for hair loss.
Is the carbonyl stress also present in the scalp and can it be one of the mechanisms involved in the occurrence of postpartum hair loss? To demonstrate this, samples of hair follicles are taken. The proteins are extracted from the samples and then assayed. The oxidized (carbonyl) proteins are labeled with specific fluorescent probes
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Toulouse, France, 31059
- Hopital Purpan
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Criteria related to the Population:
- Pregnant woman (≥ 33 weeks of amenorrhea)
- Woman aged between 18 and 40 years (included)
- Phototype I to IV included according to Fitzpatrick's classification
- Affiliation to a French social security scheme or benefiting from such a scheme
- Signed informed consent form
Exclusion Criteria:
Criteria related to the Population:
- High risk or pathological pregnancy, according to the opinion of the investigator
- Deprivation of liberty by administrative or judicial decision or subject under guardianship
- Impossibility, according to the investigator, to comply with the requirements of the protocol
- Linguistic or psychic incapacity to sign informed consent
- Concomitant participation in a clinical study that may interfere with the results of the study, according to the opinion of the investigator (excluding observational studies)
Criteria related to Pathology :
- Alopecia causing hair loss on the upper part of the scalp
- Dermatological pathology or evolving cutaneous lesion in the scalp
- Known history of hepatitis B and C, HIV
- Past or present neoplastic condition
- Acute evolving pathology
- Gestational diabetes treated with insulin
Criteria related to Treatments:
- Treatment of general thyroid disorders initiated or modified for less than 3 months prior to inclusion (or change of specialty for less than 3 months)
- Systemic treatment affecting hair growth taken for at least 4 weeks during the 3 months prior to inclusion
- Systemic treatment: nonsteroidal anti-inflammatory drug, corticosteroid, antibiotic, antihistamine taken for 5 consecutive days within 2 weeks prior to inclusion or that may interfere with the results of the study according to the investigator,
- Dermal use, for at least 4 weeks, of Minoxidil, Aminexil within 3 months prior to inclusion
- Dermal use in the 4 weeks prior to inclusion, of any product that may be active on the hair follicle and scalp or may affect the dosage of carbonyl compounds (including hair dyes)
- Last shampoo less than 2 days before the inclusion and application of styling / care products (gel, lacquer, wax, conditioner ...) or water between the last shampoo and the inclusion
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: Intra individual
Before and after pregnancy, hair follicles will be analysed
|
The hair follicles will be collected by strand of 5 to 6 hairs approximately in the scalp (centro-parietal part), in order to obtain 20 follicles with epithelial sheath.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change of biological evaluation
Time Frame: 1st sample: inclusion visit (up to 8 weeks before delivery)- 2nd sample: end of study visit (10 to 16 weeks after delivery)
|
Evaluation of the quantity of carbonyl compounds measured in the hair follicles taken before and after delivery.
|
1st sample: inclusion visit (up to 8 weeks before delivery)- 2nd sample: end of study visit (10 to 16 weeks after delivery)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Safety evaluation
Time Frame: From inclusion to end of study
|
Adverse events evaluation for all subjects, all along the study
|
From inclusion to end of study
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Christophe VAYSSIERE, MD
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- STRESSCARBONYL2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Telogen Effluvium
-
Olistic Research Labs S.L.Grupo Dermatologico Y Estetico Pedro Jaen S.A.Recruiting
-
Derming SRLCompletedTelogen Effluvium
-
EMSLuxbiotechCompleted
-
Pierre Fabre Dermo CosmetiqueCompleted
-
Olistic Research Labs S.L.Completed
-
Kasr El Aini HospitalCompleted
-
Biolab Sanus FarmaceuticaNot yet recruiting
-
Pierre Fabre Dermo CosmetiqueCompleted
-
Northwestern UniversityTerminatedAndrogenetic Alopecia | Alopecia Areata | Telogen EffluviumUnited States
-
Lacer S.A.CompletedAndrogenetic Alopecia | Telogen EffluviumSpain
Clinical Trials on Hair follicles sampling
-
Pierre Fabre Dermo CosmetiqueCompleted
-
Rabin Medical CenterCompleted
-
Meir Medical CenterCompleted
-
Hopital FochActive, not recruiting
-
Weill Medical College of Cornell UniversityCompleted
-
Azienda Ospedaliera Universitaria Integrata VeronaSocieta Italiana dell'Ipertensione ArteriosaNot yet recruitingDyslipidemias | Treatment Adherence | Arterial Hypertension | Antihypertensive Drugs | StatinsItaly
-
University Hospital, BordeauxRecruitingBehavioral Symptoms | Mental Disorders | Depression | Brain Diseases | Neurocognitive Disorders | Dementia | Anxiety | Alzheimer Disease | Aging | Mental Health | Immunosenescence | Cognition | Brain | Cognitive Aging | Mental ProcessesFrance
-
Sohag UniversityNot yet recruiting
-
NovoBliss Research Pvt LtdCompleted